نتائج البحث - Angela Alistar

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    Dual roles for immune metagenes in breast cancer prognosis and therapy prediction

    Dual roles for immune metagenes in breast cancer prognosis and therapy prediction حسب Angela Alistar, Jeff W. Chou, Srikanth Nagalla, Michael A. Black, Ralph B. D’Agostino, Lance D. Miller

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (MFFX) versus FOLFIRINOX (FFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

    A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (MFFX) versus FOLFIRINOX (FFX) in Patients with Metastatic Adenocarcinoma of the Pa... حسب Philip A. Philip, Marc Buyse, Angela Alistar, Caio M.S. Rocha Lima, Sanjeev Luther, Timothy S. Pardee, Eric Van Cutsem

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma

    A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma حسب Thomas Lycan, Timothy S. Pardee, W. Jeffrey Petty, Marcelo Bonomi, Angela Alistar, Zanetta S. Lamar, Scott Isom, Michael D. Chan, Antonius A. Miller, Jimmy Ruiz

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies

    Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies حسب Jay Jacoby, Deva Mahalingam, Angela Alistar, Edward G. Garmey, Syed Mohammad Ali Kazmi, Teresa Mooneyham, Lijun Sun, Timothy A. Yap, Peter Vu, Justin C. Moser

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness

    Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness حسب Lance D. Miller, Jeff Chou, Michael A. Black, Cristin G. Print, Julia Chifman, Angela Alistar, Thomas Choudary Putti, Xiaobo Zhou, Davide Bedognetti, Wouter Hendrickx, Ashok Pullikuth, Jonathan Rennhack, Eran R. Andrechek, Sandra Demaria, Ena Wang, Francesco M. Marincola

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

    Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein حسب Andrew Ferretti, Tomasz Kula, Yifan Wang, Dalena M.V. Nguyen, Adam Weinheimer, Garrett S. Dunlap, Qikai Xu, Nancy Nabilsi, Candace R. Perullo, Alexander Cristofaro, Holly Whitton, Amy Virbasius, Kenneth J. Olivier, Lyndsey R. Buckner, Angela Alistar, Eric D. Whitman, Sarah A. Bertino, Shrikanta Chattopadhyay, Gavin MacBeath

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

    Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial حسب Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliú, Mariano Ponz‐Sarvisé, David Gutiérrez Abad, Paul E. Oberstein, Angela Alistar, Andrés Muñoz, Ravit Geva, Carmen Guillén‐Ponce, Mercedes Salgado Fernández, Amnon Peled, Marya Chaney, Irit Gliko‐Kabir, Liron Shemesh-Darvish, Debby Ickowicz, Ella Sorani, Shaul Kadosh, Abi Vainstein‐Haras, Manuel Hidalgo

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

    Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose... حسب Angela Alistar, Bonny Morris, Rodwige Desnoyer, Heidi D. Klepin, Keyanoosh Hosseinzadeh, Clancy J. Clark, A. L. Cameron, John R. Leyendecker, Ralph B. D’Agostino, Ümit Topaloĝlu, Lakmal W. Boteju, Asela Boteju, Rob Shorr, Zuzana Zachar, Paul M. Bingham, Tamjeed Ahmed, Sandrine Crane, Riddhishkumar Shah, John Joseph Migliano, Timothy S. Pardee, Lance D. Miller, Gregory A. Hawkins, Guangxu Jin, Wei Zhang, Boris Pasche

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: